Rethinking statistical approaches to evaluating drug safety

Yonsei Medical Journal

Volumn 48, Issue 6, 2007, Pages 895-900

  Liu, Jen Pei ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Effectiveness; No excessive risk; Non inferiority approach; Safety

Indexed keywords

CELECOXIB; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; ROSIGLITAZONE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HAZARD RATIO; HEART INFARCTION; HUMAN; MORTALITY; REVIEW; RISK; RISK ASSESSMENT; STATISTICAL ANALYSIS; THROMBOSIS;

BIOMETRY; CONFIDENCE INTERVALS; CONTROLLED CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG EVALUATION; DRUG TOXICITY; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN;

EID: 38049148618     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2007.48.6.895     Document Type: Review

References (16)

1. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
2. Topol EJ. Failing the public health-refecoxib, Merck, and FDA. N Engl J Med 2004;351:1707-9.
3. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgin K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
5. Harris G. FDA issues strictest warning on diabetes drugs. New York Times 2007 Jun 6. Available from: http://www.nytimes.com/2007/06/07/health/ 07drug.htm.
6. Hauschke D, Hothorn LA. Safety, assessment of toxicological studies: proof of safety versus proof of hazard. In: Chow SC, Liu JP, editors. Design and analysis of animal studies in pharmaceutical development. New York: Marcel Dekker, Inc.; 1995. p.197-225.
7. Colton T. Statistics in medicine. Boston (MA): Little, Brown and Company; 1974.
8. Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. 2nd ed. New York (NY): Marcel Dekker, Inc.; 2000.
9. Chow SC, Liu JP. Design and analysis of Clinical Trials. 2nd ed. New York (NY): John Wiley and sons, 2004.
10. Farrington CP, Manning G. Test statistics and sample size formulae for comparing binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990;9:1447-54.
11. Liu JP, Hsueh HM, Hsieh E, Chen JJ. Tests for equivalence or non-inferiority for paired binary data. Stat Med 2003;21:231-45.
12. Hsueh HM, Liu JP, Chen JJ. Unconditional exact tests for equivalence or non-inferiority for paired binary endpoints. Biometrics 2001;57:478-83.
13. Chan ISF. Proving non-inferiority or equivalence of two treatments with dichotomous endpoints using exact methods. Stat Methods Med Res 2003;12:37-58.
14. Liu JP, Fan HY, Ma MC. Tests for equivalence based on odds ratio for matched-pair design. J Biopharm Stat 2005:15:889-901.
15. Tang NS, Tang ML, Wang SF. Sample size determination for matched-pair equivalence trials using rate ratio. Biostatistics 2007;8:625-31.
16. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis, N Engl J Med 2007;357:28-38.